(0.33%) 5 116.77 points
(0.33%) 38 365 points
(0.37%) 15 986 points
(-0.93%) $83.07
(5.56%) $2.03
(0.34%) $2 355.20
(0.42%) $27.65
(4.01%) $959.05
(-0.25%) $0.932
(-0.39%) $10.98
(-0.56%) $0.796
(1.69%) $93.43
Quarter results tomorrow
(amc 2024-04-30)
Expected move: +/- 5.00%
@ $23.70
発行日: 27 4月 2024 @ 04:47
リターン: 0.15%
前回のシグナル: 4月 26 - 02:51
前回のシグナル:
リターン: 0.87 %
Live Chart Being Loaded With Signals
Exelixis, Inc., an oncology-focused biotechnology company, focuses on the discovery, development, and commercialization of new medicines to treat cancers in the United States...
Stats | |
---|---|
本日の出来高 | 471 688 |
平均出来高 | 2.24M |
時価総額 | 7.00B |
EPS | $0 ( 2024-02-06 ) |
次の収益日 | ( $0.280 ) 2024-04-30 |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E | 36.52 |
ATR14 | $0.294 (1.24%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-03-21 | Garber Alan M | Buy | 23 491 | Common Stock |
2024-03-21 | Garber Alan M | Sell | 19 205 | Common Stock |
2024-03-21 | Garber Alan M | Sell | 23 491 | Option (right to buy) |
2024-02-23 | Peterson Amy C. | Buy | 82 121 | Common Stock |
2024-02-23 | Aftab Dana | Buy | 63 350 | Common Stock |
INSIDER POWER |
---|
27.66 |
Last 94 transactions |
Buy: 3 435 845 | Sell: 2 083 268 |
ボリューム 相関
Exelixis Inc 相関
10 最も正の相関 | |
---|---|
NVEI | 0.902 |
ARRW | 0.897 |
ARDX | 0.891 |
NBST | 0.891 |
LCYAU | 0.889 |
EBACU | 0.888 |
LCY | 0.886 |
RCII | 0.882 |
DAKT | 0.882 |
JNCE | 0.879 |
10 最も負の相関 | |
---|---|
GCBC | -0.91 |
SRCE | -0.895 |
GSBC | -0.895 |
HTBK | -0.887 |
ORPH | -0.886 |
BMRC | -0.885 |
SFST | -0.884 |
EQBK | -0.883 |
PTVE | -0.883 |
BWB | -0.883 |
知っていましたか?
相関は、2つの変数間の関係を説明する統計的指標です。相関係数は-1から1までの値を取り、-1は完全な負の相関(1つの変数が増加すると、もう一方は減少する)、1は完全な正の相関(1つの変数が増加すると、もう一方も増加する)、0は相関がないことを示します(変数間に関係がない)。
相関は、株式だけでなく、どの2つの変数間の関係にも適用できます。これは、金融、経済学、心理学などの分野で一般的に使用されています。
Exelixis Inc 相関 - 通貨/商品
Exelixis Inc 財務諸表
Annual | 2023 |
収益: | $1.83B |
総利益: | $1.76B (96.04 %) |
EPS: | $0.650 |
FY | 2023 |
収益: | $1.83B |
総利益: | $1.76B (96.04 %) |
EPS: | $0.650 |
FY | 2022 |
収益: | $1.61B |
総利益: | $1.55B (96.41 %) |
EPS: | $0.570 |
FY | 2021 |
収益: | $1.43B |
総利益: | $1.38B (96.32 %) |
EPS: | $0.733 |
Financial Reports:
No articles found.
Exelixis Inc
Exelixis, Inc., an oncology-focused biotechnology company, focuses on the discovery, development, and commercialization of new medicines to treat cancers in the United States. The company's products include CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of patients with progressive and metastatic medullary thyroid cancer. Its CABOMETYX and COMETRIQ are derived from cabozantinib, an inhibitor of multiple tyrosine kinases, including MET, AXL, RET, and VEGF receptors. The company also offers COTELLIC, an inhibitor of MEK as a combination regimen to treat advanced melanoma; and MINNEBRO, an oral non-steroidal selective blocker of the mineralocorticoid receptor for the treatment of hypertension in Japan. In addition, it is developing XL092, an oral tyrosine kinase inhibitor that targets VEGF receptors, MET, AXL, MER, and other kinases implicated in growth and spread of cancer; XB002, an antibody-drug conjugate composed of human mAb against tissue factor (TF) for the treatment of advanced solid tumors; XL102, an orally bioavailable cyclin-dependent kinase 7 (CDK7) inhibitor for the treatment of advanced or metastatic solid tumors; and XB002 for the treatment of non-hodgkin's lymphoma. Exelixis, Inc. has research collaborations and license agreements with Ipsen Pharma SAS; Takeda Pharmaceutical Company Ltd.; F. Hoffmann-La Roche Ltd.; Redwood Bioscience, Inc.; R.P. Scherer Technologies, LLC; Catalent Pharma Solutions, Inc.; NBE Therapeutics AG; Aurigene Discovery Technologies Limited; Iconic Therapeutics, Inc.; Invenra, Inc.; StemSynergy Therapeutics, Inc.; Genentech, Inc.; Bristol-Myers Squibb Company; and Daiichi Sankyo Company, Limited. The company was formerly known as Exelixis Pharmaceuticals, Inc. and changed its name to Exelixis, Inc. in February 2000. Exelixis, Inc. was incorporated in 1994 and is headquartered in Alameda, California.
について ライブシグナル
このページで提示されるライブシグナルは、NA を買う時や売る時を判断するのに役立ちます。シグナルには1分以上の遅延があります。市場シグナルには誤りやミスの可能性があるため、ライブ取引シグナルは決定的ではなく、getagraph.comはこれらのシグナルに基づく任意の行動について責任を負いません。詳細については、利用規約で説明されているように、技術分析指標に基づいています。